Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L19-IL2 + Dacarbazine in Metastatic Melanoma
NCT02076646Phase 2Unknown
- Sponsor
- Philogen
- Start
- Jul 2013
- Primary completion
- May 2016
- Modality
- Immunomodulatory ADCs, Cytokines & Interferons, Engineered Antibody Formats
- Countries
- 2
01
Overview
A Phase 2 trial of darleukin in melanoma, sponsored by Philogen. Status: unknown.
02
Drugs
darleukin
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02076646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02076646.